CN108367053A - 使用生长分化因子15(gdf-15)治疗或改善代谢性疾病的方法 - Google Patents
使用生长分化因子15(gdf-15)治疗或改善代谢性疾病的方法 Download PDFInfo
- Publication number
- CN108367053A CN108367053A CN201680075098.4A CN201680075098A CN108367053A CN 108367053 A CN108367053 A CN 108367053A CN 201680075098 A CN201680075098 A CN 201680075098A CN 108367053 A CN108367053 A CN 108367053A
- Authority
- CN
- China
- Prior art keywords
- gdf15
- seq
- conjugate
- therapeutic agent
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 C(*1)C2=C1C*C2 Chemical compound C(*1)C2=C1C*C2 0.000 description 7
- UTUSMODCQFFHIW-UHFFFAOYSA-N CCCCCCCCCCCCCCCCCC(NS(CCCC(O)=O)(=O)=O)=O Chemical compound CCCCCCCCCCCCCCCCCC(NS(CCCC(O)=O)(=O)=O)=O UTUSMODCQFFHIW-UHFFFAOYSA-N 0.000 description 1
- YXMDAZMGKWJOAB-UHFFFAOYSA-N OC(CCCCCCCCCCCCCCCCC(NS(CCCC(O)=O)(=O)=O)=O)=O Chemical compound OC(CCCCCCCCCCCCCCCCC(NS(CCCC(O)=O)(=O)=O)=O)=O YXMDAZMGKWJOAB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562270967P | 2015-12-22 | 2015-12-22 | |
| US62/270,967 | 2015-12-22 | ||
| PCT/IB2016/057839 WO2017109706A1 (en) | 2015-12-22 | 2016-12-20 | Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108367053A true CN108367053A (zh) | 2018-08-03 |
Family
ID=57796765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680075098.4A Pending CN108367053A (zh) | 2015-12-22 | 2016-12-20 | 使用生长分化因子15(gdf-15)治疗或改善代谢性疾病的方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20190000923A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3393494A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP6946304B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN108367053A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2017109706A1 (cg-RX-API-DMAC10.html) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111333505A (zh) * | 2020-03-31 | 2020-06-26 | 东莞市东阳光生物药研发有限公司 | 制备长链脂肪二酸单苄酯的方法及其应用 |
| WO2021139763A1 (zh) * | 2020-01-08 | 2021-07-15 | 上海翰森生物医药科技有限公司 | Fgf21突变体蛋白及其融合蛋白 |
| CN113474363A (zh) * | 2018-11-20 | 2021-10-01 | 詹森药业有限公司 | 用于降低体重和/或减少食物摄取量的gdf15类似物和方法 |
| CN113767112A (zh) * | 2019-04-23 | 2021-12-07 | 株式会社Lg化学 | 包含免疫球蛋白Fc区和GDF15的融合多肽 |
| WO2022089435A1 (en) * | 2020-10-27 | 2022-05-05 | Beijing Ql Biopharmaceutical Co., Ltd. | Fusion proteins of gdf15 and use thereof |
| CN118995820A (zh) * | 2024-10-22 | 2024-11-22 | 江苏凯基生物技术股份有限公司 | 一种生长分化因子-15及其制备方法 |
| US12275770B2 (en) | 2018-10-22 | 2025-04-15 | Janssen Sciences Ireland Unlimited Company | Glucagon like peptide 1 (GLP1)-growth differentiation factor 15 (GDF15) fusion proteins and uses thereof |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5977814B2 (ja) | 2011-04-08 | 2016-08-24 | アムジエン・インコーポレーテツド | 増殖分化因子15(gdf−15)を使用して代謝障害を治療または改善する方法 |
| JP6254146B2 (ja) | 2012-03-27 | 2017-12-27 | エヌジーエム バイオファーマシューティカルス,インコーポレーテッド | 代謝障害を治療するための組成物および方法 |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| LT3027642T (lt) | 2013-07-31 | 2020-10-12 | Amgen Inc. | Augimo ir diferenciacijos faktoriaus 15(gdf-15) konstruktai |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| JP6704358B2 (ja) | 2014-07-30 | 2020-06-03 | エヌジーエム バイオファーマシューティカルズ インコーポレイテッド | 代謝障害を治療するための組成物および使用方法 |
| US10004596B2 (en) | 2014-07-31 | 2018-06-26 | Lensgen, Inc. | Accommodating intraocular lens device |
| CN106687128B (zh) | 2014-10-31 | 2022-05-10 | Ngm生物制药有限公司 | 用于治疗代谢病症的组合物和方法 |
| JP7296728B2 (ja) * | 2015-10-23 | 2023-06-23 | メルス ナムローゼ フェンノートシャップ | 癌の成長を抑制する結合分子 |
| KR102433503B1 (ko) | 2016-05-24 | 2022-08-18 | 노보 노르디스크 에이/에스 | Mic-1 화합물 및 이것의 사용 |
| EP3538124A4 (en) * | 2016-11-13 | 2020-07-22 | Imagine Pharma | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES, HYPERTENSION AND HYPERCHOLESTEROLEMIA |
| TWI710377B (zh) * | 2017-05-23 | 2020-11-21 | 丹麥商諾佛 儂迪克股份有限公司 | Mic-1化合物及其用途 |
| JP2020533302A (ja) | 2017-09-10 | 2020-11-19 | ノヴォ ノルディスク アー/エス | 肥満の治療において使用するためのmic−1およびglp−1 |
| TWI724392B (zh) * | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | 生長分化因子15促效劑化合物及其使用方法 |
| US12054527B2 (en) * | 2018-04-09 | 2024-08-06 | Amgen Inc. | Growth differentiation factor 15 fusion proteins |
| WO2020009740A2 (en) * | 2018-04-25 | 2020-01-09 | Washington University | Compositions and methods of use thereof for treatment of metabolic diseases and related disorders |
| EP3833974A2 (en) | 2018-08-10 | 2021-06-16 | Novartis AG | Gfral extracellular domains and methods of use |
| US20220098252A1 (en) | 2019-01-25 | 2022-03-31 | Ospedale San Raffaele S.R.L. | Inhibitor of dux4 and uses thereof |
| ES3061099T3 (en) | 2019-10-04 | 2026-03-31 | Amgen Inc | Use of gdf15 for treating cardiometabolic syndrome and other conditions |
| EP4081241A4 (en) * | 2019-12-24 | 2024-05-01 | Juvena Therapeutics, Inc. | REGENERATIVE POLYPEPTIDES AND USES THEREOF |
| WO2021136223A1 (en) | 2019-12-31 | 2021-07-08 | Beijing Ql Biopharmaceutical Co., Ltd. | Fusion proteins of glp-1 and gdf15 and conjugates thereof |
| KR102569644B1 (ko) * | 2020-10-30 | 2023-08-23 | 가톨릭대학교 산학협력단 | Gdf15를 유효성분으로 함유하는 면역질환의 예방 및 치료용 조성물 |
| WO2022219495A1 (en) | 2021-04-12 | 2022-10-20 | Novartis Ag | 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity |
| EP4351627A4 (en) * | 2021-05-21 | 2025-06-04 | Yuhan Corporation | COMPOSITION FOR COMBINATION THERAPY COMPRISING A GROWTH DIFFERENTIATION FACTOR 15 VARIANT AND A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST |
| AU2022278933A1 (en) * | 2021-05-21 | 2023-12-07 | Yuhan Corporation | Composition for preventing or treating non-alcoholic fatty liver disease or non-alcoholic steatohepatitis comprising growth differentiation factor-15 variant |
| JP2025505198A (ja) | 2022-02-10 | 2025-02-21 | ノバルティス アーゲー | 肥満の治療のためのglp1受容体の活性化因子としての2-((4-((s)-2-(4-クロロ-2-フルオロフェニル)-2-メチルベンゾ[d][1,3]ジオキソール-4-イル)ピペリジン-1-イル)メチル)-1-(((s)-オキセタン-2-イル)メチル)-1h-イミダゾール誘導体 |
| WO2023154953A1 (en) | 2022-02-14 | 2023-08-17 | Ngm Biopharmaceuticals, Inc. | Gdf15 polypeptides for treating and preventing autoimmune diseases |
| JP2024058473A (ja) * | 2022-10-14 | 2024-04-25 | 国立大学法人九州大学 | 筋線維芽細胞のα-平滑筋アクチン及びコラーゲンの発現抑制剤、線維症治療用医薬組成物、並びに、in vitroで筋線維芽細胞のα-平滑筋アクチン及びコラーゲンの産生を抑制する方法 |
| EP4389762A1 (en) | 2022-12-23 | 2024-06-26 | Ospedale San Raffaele S.r.l. | Inhibitors of dux4 activity and their use in therapy. |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103533951A (zh) * | 2011-04-08 | 2014-01-22 | 安姆根有限公司 | 使用生长分化因子15(gdf-15)治疗或改善代谢障碍的方法 |
| CN103945695A (zh) * | 2011-09-16 | 2014-07-23 | 卡莱克汀医疗有限公司 | 用于治疗非酒精性脂肪性肝炎和非酒精性脂肪肝病的半乳糖-鼠李糖半乳糖醛酸酯组合物 |
| WO2014120619A2 (en) * | 2013-01-30 | 2014-08-07 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use in treating metabolic disorders |
| CN104204218A (zh) * | 2012-01-26 | 2014-12-10 | 安姆根有限公司 | 生长分化因子15 (gdf-15)多肽 |
| CN107073130A (zh) * | 2014-06-23 | 2017-08-18 | 诺华股份有限公司 | 脂肪酸及其在与生物分子缀合中的用途 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
| ATE92107T1 (de) | 1989-04-29 | 1993-08-15 | Delta Biotechnology Ltd | N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen. |
| US5288931A (en) * | 1991-12-06 | 1994-02-22 | Genentech, Inc. | Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation |
| ATE423788T1 (de) | 1995-06-22 | 2009-03-15 | St Vincents Hosp Sydney | Neues tgf-beta-ahnliches cytokin |
| WO1998019523A1 (fr) * | 1996-11-01 | 1998-05-14 | Shionogi & Co., Ltd. | Souris modele pour maladies affectant l'homme |
| GB9912350D0 (en) * | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
| US6926898B2 (en) | 2000-04-12 | 2005-08-09 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| ES2464532T3 (es) | 2001-04-19 | 2014-06-03 | The Scripps Research Institute | Métodos y composiciones para la producción de pares ortogonales de ARNt-aminoacil-ARNt sintetasa |
| FI117667B (fi) * | 2001-07-05 | 2007-01-15 | Univ Zuerich | Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä |
| US20030138417A1 (en) | 2001-11-08 | 2003-07-24 | Kaisheva Elizabet A. | Stable liquid pharmaceutical formulation of IgG antibodies |
| TW200303742A (en) | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
| WO2003059934A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| AR044399A1 (es) | 2003-05-20 | 2005-09-14 | Novartis Ag | Compuestos heterociclicos y su uso como activadores de receptores de ppar. composiciones farmaceuticas que los contienen |
| EP1670515A2 (en) | 2003-09-19 | 2006-06-21 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| CN102816241B (zh) | 2004-02-09 | 2015-07-22 | 人类基因科学公司 | 清蛋白融合蛋白 |
| US8431558B2 (en) | 2004-11-01 | 2013-04-30 | The Regents Of The University Of California | Compositions and methods for modification of biomolecules |
| TW200738261A (en) | 2005-12-20 | 2007-10-16 | Bristol Myers Squibb Co | Stable protein formulations |
| CA2722829A1 (en) * | 2008-05-06 | 2009-11-12 | F. Hoffmann-La Roche Ag | Animal model for diabetes |
| JP5542832B2 (ja) | 2008-10-24 | 2014-07-09 | アイアールエム・リミテッド・ライアビリティ・カンパニー | 生合成的に製造したピロリン−カルボキシ−リシンならびにピロリン−カルボキシ−リシンおよびピロリシン基の化学誘導体化を介する部位特異的タンパク質修飾 |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| WO2012106615A1 (en) * | 2011-02-03 | 2012-08-09 | Xoma Technology Ltd. | Methods and materials for enhancing functional protein expression in bacteria |
| JP6254146B2 (ja) * | 2012-03-27 | 2017-12-27 | エヌジーエム バイオファーマシューティカルス,インコーポレーテッド | 代謝障害を治療するための組成物および方法 |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| LT3027642T (lt) | 2013-07-31 | 2020-10-12 | Amgen Inc. | Augimo ir diferenciacijos faktoriaus 15(gdf-15) konstruktai |
| CA2952032C (en) * | 2014-06-20 | 2023-03-14 | Aveo Pharmaceuticals, Inc. | Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator |
| EP3157947A1 (en) | 2014-06-23 | 2017-04-26 | Novartis AG | Hsa-gdf-15 fusion polypeptide and use thereof |
| CN106573955B (zh) | 2014-06-23 | 2021-02-26 | 诺华股份有限公司 | 位点特异性蛋白质修饰 |
| WO2015197446A1 (en) | 2014-06-24 | 2015-12-30 | Novo Nordisk A/S | Mic-1 fusion proteins and uses thereof |
| WO2016102580A1 (en) | 2014-12-22 | 2016-06-30 | Novo Nordisk A/S | Alpha-1-antitrypsin (a1at) fusion proteins and uses thereof |
-
2016
- 2016-12-20 US US16/064,054 patent/US20190000923A1/en not_active Abandoned
- 2016-12-20 WO PCT/IB2016/057839 patent/WO2017109706A1/en not_active Ceased
- 2016-12-20 JP JP2018532639A patent/JP6946304B2/ja not_active Expired - Fee Related
- 2016-12-20 EP EP16826174.1A patent/EP3393494A1/en not_active Withdrawn
- 2016-12-20 CN CN201680075098.4A patent/CN108367053A/zh active Pending
-
2022
- 2022-04-14 US US17/720,555 patent/US20220249614A1/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103533951A (zh) * | 2011-04-08 | 2014-01-22 | 安姆根有限公司 | 使用生长分化因子15(gdf-15)治疗或改善代谢障碍的方法 |
| CN103945695A (zh) * | 2011-09-16 | 2014-07-23 | 卡莱克汀医疗有限公司 | 用于治疗非酒精性脂肪性肝炎和非酒精性脂肪肝病的半乳糖-鼠李糖半乳糖醛酸酯组合物 |
| CN104204218A (zh) * | 2012-01-26 | 2014-12-10 | 安姆根有限公司 | 生长分化因子15 (gdf-15)多肽 |
| WO2014120619A2 (en) * | 2013-01-30 | 2014-08-07 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use in treating metabolic disorders |
| CN107073130A (zh) * | 2014-06-23 | 2017-08-18 | 诺华股份有限公司 | 脂肪酸及其在与生物分子缀合中的用途 |
Non-Patent Citations (3)
| Title |
|---|
| HSIAO E.C.等: "Characterization of growth-differentiation factor 15, a transforming growth factor β superfamily member induced following liver injury", 《MOLECULAR AND CELLULAR BIOLOGY》 * |
| 李岩: "《消化系统与疾病》", 30 April 2008 * |
| 林三仁: "《实用临床消化病学》", 31 October 2007 * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12275770B2 (en) | 2018-10-22 | 2025-04-15 | Janssen Sciences Ireland Unlimited Company | Glucagon like peptide 1 (GLP1)-growth differentiation factor 15 (GDF15) fusion proteins and uses thereof |
| CN113474363A (zh) * | 2018-11-20 | 2021-10-01 | 詹森药业有限公司 | 用于降低体重和/或减少食物摄取量的gdf15类似物和方法 |
| CN113767112A (zh) * | 2019-04-23 | 2021-12-07 | 株式会社Lg化学 | 包含免疫球蛋白Fc区和GDF15的融合多肽 |
| WO2021139763A1 (zh) * | 2020-01-08 | 2021-07-15 | 上海翰森生物医药科技有限公司 | Fgf21突变体蛋白及其融合蛋白 |
| CN111333505A (zh) * | 2020-03-31 | 2020-06-26 | 东莞市东阳光生物药研发有限公司 | 制备长链脂肪二酸单苄酯的方法及其应用 |
| WO2021197303A1 (zh) * | 2020-03-31 | 2021-10-07 | 东莞市东阳光生物药研发有限公司 | 制备长链脂肪二酸单苄酯的方法及其应用 |
| CN111333505B (zh) * | 2020-03-31 | 2022-07-26 | 东莞市东阳光生物药研发有限公司 | 制备长链脂肪二酸单苄酯的方法及其应用 |
| WO2022089435A1 (en) * | 2020-10-27 | 2022-05-05 | Beijing Ql Biopharmaceutical Co., Ltd. | Fusion proteins of gdf15 and use thereof |
| CN115244076A (zh) * | 2020-10-27 | 2022-10-25 | 北京质肽生物医药科技有限公司 | Gdf15融合蛋白及其用途 |
| US11884711B2 (en) | 2020-10-27 | 2024-01-30 | Beijing Ql Biopharmaceutical Co., Ltd. | Fusion proteins of GDF15 and use thereof |
| CN118995820A (zh) * | 2024-10-22 | 2024-11-22 | 江苏凯基生物技术股份有限公司 | 一种生长分化因子-15及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20190000923A1 (en) | 2019-01-03 |
| JP6946304B2 (ja) | 2021-10-06 |
| WO2017109706A1 (en) | 2017-06-29 |
| JP2018538335A (ja) | 2018-12-27 |
| EP3393494A1 (en) | 2018-10-31 |
| US20220249614A1 (en) | 2022-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220249614A1 (en) | Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) | |
| US20230115655A1 (en) | Engineered polypeptides having enhanced duration of action | |
| US20200181216A1 (en) | Hsa-gdf-15 fusion polypeptide and use thereof | |
| US9879063B2 (en) | Engineered polypeptides having enhanced duration of action and reduced immunogenicity | |
| JP2020045362A (ja) | グルカゴン−glp−1−gipトリプルアゴニスト化合物 | |
| TW201427993A (zh) | 用於治療肥胖之升糖素與glp-1共促效劑 | |
| HK1225307A1 (en) | Engineered polypeptides having enhanced duration of action | |
| KR20160079875A (ko) | Gip-glp-1 이원 효능제 화합물 및 방법 | |
| CN116635402B (zh) | 用于代谢病症的融合多肽 | |
| WO2013148871A1 (en) | Engineered polypeptides | |
| US12551541B2 (en) | Albumin bound macromolecule tri-agonist activating GLP 1/GIP/glucagon receptors and methods therefor | |
| KR20220125289A (ko) | Fgf-21 접합체 제제 | |
| HK1188924B (en) | Leptin-abd fusion polypeptides with enhanced duration of action | |
| HK1188924A (en) | Leptin-abd fusion polypeptides with enhanced duration of action | |
| HK1196093B (en) | Engineered polypeptides having enhanced duration of action and reduced immunogenicity | |
| HK1196093A (en) | Engineered polypeptides having enhanced duration of action and reduced immunogenicity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |